DEFA14A: TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

TransCode Therapeutics is asking shareholders to authorize a reverse stock split to maintain its Nasdaq listing, which is crucial for raising capital and avoiding delisting.

Summary

• TransCode Therapeutics is seeking shareholder approval for a reverse stock split.
• The reverse split is contingent on the company's stock price not reaching $1.00 per share for ten consecutive days before December 31, 2024.
• The Nasdaq Hearings Panel has mandated the authorization of a reverse split as a condition for continued listing.
• Failure to authorize the reverse split could result in delisting from Nasdaq, which would likely have a material adverse effect on the company's value.
• The company believes maintaining its Nasdaq listing is critical for raising necessary capital to continue clinical trials and operations.
• Management and directors are unanimously in favor of maintaining the Nasdaq listing.

Sentiment

Score: 3

Explanation: The document conveys a sense of urgency and concern about the company's stock price and Nasdaq listing. The need for a reverse split and the risk of delisting are negative indicators, although the management is trying to be positive.

Positives

• The company is actively working to maintain its Nasdaq listing.
• Management and directors are unanimously determined to maintain the Nasdaq listing.
• The company believes that maintaining its Nasdaq listing is critical for raising needed capital.

Negatives

• The company's stock price is currently below the Nasdaq minimum requirement of $1.00 per share.
• The company may need to implement a reverse stock split to avoid delisting.
• Delisting from Nasdaq would likely have a material adverse effect on the company's value and stock price.

Risks

• The company's stock price may not reach $1.00 per share for ten consecutive days before December 31, 2024.
• Shareholders may not approve the reverse stock split.
• Delisting from Nasdaq could significantly impact the company's ability to raise capital and continue operations.
• There is no guarantee that positive clinical data will be released or that the stock price will increase even if positive news is announced.

Future Outlook

The company's future depends on maintaining its Nasdaq listing, which is contingent on the stock price reaching $1.00 or shareholder approval of a reverse stock split. The company needs to raise additional capital to continue clinical trials and operations.

Management Comments

• A reverse split is NOT something directors or management wishes to do.
• TransCodes management and directors are unanimously determined to maintain our Nasdaq listing.
• We call for your understanding and greatly appreciate your support.

Industry Context

Many small biotech companies face challenges in maintaining their stock price and Nasdaq listing, especially during clinical trials. This situation is not unique to TransCode, and the need for a reverse split is a common strategy to avoid delisting.

Comparison to Industry Standards

• Many small cap biotech companies face similar challenges with maintaining their stock price above the Nasdaq minimum bid price.
• Reverse stock splits are a common mechanism used by companies to regain compliance with listing requirements.
• Companies such as Agenus Inc. and Cellectar Biosciences have also recently undertaken reverse stock splits to maintain their Nasdaq listings.

Stakeholder Impact

• Shareholders face the risk of a reverse stock split and potential delisting, which could negatively impact their investment.
• The company's ability to raise capital and continue operations is at risk if the Nasdaq listing is not maintained.
• Employees may be impacted by the company's financial situation and potential delisting.

Next Steps

• Shareholders will vote on the reverse stock split at the Special Meeting on November 22, 2024.
• The company needs to ensure the stock price reaches $1.00 for ten consecutive days before December 31, 2024, to avoid the reverse split.
• The company needs to raise additional capital to continue clinical trials and operations.

Key Dates

Keywords

reverse stock split, Nasdaq listing, delisting, capital raise, shareholder vote, clinical trials, stock price